1.Berger, RMF. Possibilities and impossibilities in the evaluation of pulmonary vascular disease in congenital heart defects. Eur Heart J 2000; 21: 17–27; [review].
2.Wilkinson, JL. Congenital heart disease: haemodynamic calculations in the catheter laboratory. Heart 2001; 85: 113–120.
3.Laird, TH, Stayer, SA, Rivenes, SM, et al. Pulmonary-to-systemic blood flow ratio effects of Sevoflurane, Isoflurane, Halothane, and Fentanyl/Midazolam with 100% oxygen in children with congenital heart disease. Anesth Analg 2002; 95: 1200–1206.
4.Williams, GD, Jones, TK, Hanson, KA, Morray, JP. The hemodynamic effects of Propofol in children with congenital heart disease. Anesth Analg 1999; 89: 1411–1416.
5.Öklü, E, Bulutcu, FS, Yalçin, Y, Ozbek, U, Cakali, E, Bayindir, O. Which anesthetic agent alters the hemodynamic status during pediatric catheterization? Comparison of Propofol versus Ketamine. J Cardiothorac Vasc Anesth 2003; 17: 686–690.
6.Berman, W Jr, Fripp, RR, Rubler, M, Alderete, L. Hemodynamic effects of Ketamine in children undergoing cardiac catheterization. Pediatr Cardiol 1990; 11: 72–76.
7.Jobeir, A, Galal, MO, Bulbul, ZR, Solymar, L, Darwish, A, Schmaltz, AA. Use of low-dose Ketamine and/or Midazolam for pediatric cardiac catheterization: is an anesthesiologist needed? Pediatr Cardiol 2003; 24: 236–243.
8.Kogan, A, Efrat, R, Katz, J, Vidne, BA. Propofol-Ketamine mixture for anesthesia in pediatric patients undergoing cardiac catheterization. J Cardiothorac Vasc Anesth 2003; 17: 691–693.
9.LaFarge, CG, Miettinen, OS. The estimation of oxygen consumption. Cardiovasc Res 1970; 4: 23–30.
10.Lindahl, SGE. Oxygen consumption and carbon dioxide elimination in infants and children during anaesthesia and surgery. Br J Anaesth 1989; 62: 70–76.
11.Bergstra, A, van Dijk, RB, Hillege, HL, Lie, KI, Mook, GA. Assumed oxygen consumption based on calculation from dye dilution cardiac output: an improved formula. Eur Heart J 1995; 16: 698–703.
12.Lundell, BPW, Casas, ML, Wallgren, CG. Oxygen consumption in infants and children during heart catheterization. Pediatr Cardiol 1996; 17: 207–213.
13.Shanahan, CL, Wilson, NJ, Gentles, TL, Skinner, JR. The influence of measured versus assumed uptake of oxygen in assessing pulmonary vascular resistance in patients with a bidirectional Glenn anastomosis. Cardiol Young 2003; 13: 137–142.
14.Berner, M, Beghetti, M, Spahr-Schopfer, I, Oberhansli, I, Friedli, B. Inhaled nitric oxide to test the vasodilator capacity of the pulmonary vascular bed in children with long-standing pulmonary hypertension and congenital heart disease. Am J Cardiol 1996; 77: 532–535.
15.Atz, AM, Adatia, I, Lock, JE, Wessel, DL. Combined effects of nitric oxide and oxygen during acute pulmonary vasodilator testing. J Am Coll Cardiol 1999; 33: 813–819.
16.Balzer, DT, Kort, HW, Day, RW, et al. Inhaled nitric oxide as a preoperative test (INOP test I). Circulation 2002; 106 [Suppl I]: I-76–I-81.
17.Khambdkone, S, Li, J, de Leval, MR, Cullen, S, Deanfield, JE, Redington, AN. Basal pulmonary vascular resistance and nitric oxide responsiveness late after Fontan-type operation. Circulation 2003; 107: 3204–3208.
18.Mair, DD, Hagler, DJ, Puga, FJ, Schaff, HV, Danielson, GK. Fontan operation in 176 patients with tricuspid atresia: results and a proposed new index for patient selection. Circulation 1990; 82 (Suppl): IV169–IV169.
19.Roberts, JD Jr, Lang, P, Bigatello, LM, Vlahakes, GJ, Zapol, WM. Inhaled nitric oxide in congenital heart disease. Circulation 1993; 87: 447–453.
20.Rimensberger, PC, Spahr-Schopfer, I, Berner, M, et al. Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease. Vasodilator capacity and cellular mechanisms. Circulation 2001; 103: 544–548.
21.Cannon, BC, Feltes, TF, Fraley, JK, Grifka, RG, Riddle, EM, Kovalchin, JP. Nitric oxide in the evaluation of congenital heart disease with pulmonary hypertension: factors related to nitric oxide response. Pediatr Cardiol 2005; 26: 565–569.
22.Turanlahti, MI, Laitinen, PO, Sarna, SJ, Pesonen, E. Nitric oxide, oxygen, and prostacyclin in children with pulmonary hypertension. Heart 1998; 79: 169–174.